Table 2. Univariate analysis of clinicopathological variables at primary melanoma diagnosis associated with brain metastasis-free survival.

Cox proportional hazards analysis assuming the absence (A) and presence (B) of competing risks.

Variable	Cox PH Analysis				Cox PH Analysis Under Competing Risk
	MCG		IMCG		MCG		IMCG
	HR (95% CI)	P	HR (95% CI)	P	HR(95% CI)	P	HR(95% CI)	P
Primary tumor thickness (mm)a	3.29 (2.50–4.33)	<.0001	2.21 (1.78–2.54)	<.0001	2.81(2.2–3.58)	<.0001	1.99(1.69–2.34)	<.0001
Primary tumor ulceration status
Present vs. absent	4.49(2.91–6.93)	<.0001	5.58(3.47–7.28)	<.0001	3.96(2.57–6.1)	<.0001	5(3.4–7.36)	<.0001
Primary tumor mitosis
Present vs. absent	2.53 (1.48–4.35)	0.0008	2.84 (.178–4.88)	<.0001	2.37(1.38–4.05)	0.002	2.67(1.61–4.44)	0.0002
AJCC stage at pathological diagnosis
III/IV vs. I/II	5.91(3.76–9.30)	<.0001	5.63 (3.72–7.39)	<.0001	4.63(2.94–7.29)	<.0001	4.67(3.25–6.71)	<.0001
Primary tumor histotype
Nodular vs. superficial spreading/other	2.97 (1.76–5.04)	<.0001	3.06 (2.01–4.24)	<.0001	2.74(1.62–4.64)	<.0001	2.83(1.91–4.19)	<.0001
Primary tumor anatomic site
Head/neck vs. others	1.18(0.65–2.13)	0.59	2.16(1.44–3.24)	0.0004	1.11(0.61–2.00)	0.74	2.03(1.33–3.10)	0.001
Gender
Male vs. female	1.88 (1.20–2.94)	0.005	1.26(0.89–1.79)	0.200	1.81 (1.16–2.82)	0.009	1.24(0.87–1.77)	0.24